- Supported exchanges /
- SHE /
- 300683.SHE
Wuhan Hiteck Biological Pharma Co Ltd (300683 SHE) stock market data APIs
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; indometacin and furazolidone suppositories for internal and external hemorrhoids, anal swelling, fistula, and other anorectal diseases; tinidazole suppositories for trichomonas vaginitis and bacterial vaginosis; nimodipine sustained release tablets for ischemic cerebrovascular disease, migraine, and cerebral vasospasm; trimetazidine dihydrochloride tablets for treatment of stable angina; and azithromycin granules for treatment of acute pharyngitis, tonsillitis, and bronchitis. The company also provides measles and rubella virus nucleic acid detection kit; isolation and identification tube and kit for mycoplasma; and bacterial vaginosis (BV) rapid test kit, as well as diagnostic kit for novel coronavirus N-Protein. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kit for a "Thalassemia. Further, the company provides Lopinavir and Ritonavir APIs; and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
Wuhan Hiteck Biological Pharma Co Ltd Financial Data Overview
| 26.55 | |
| 28.15 | |
| - | |
| 28.88 | |
| 26.5 | |
| 18.8-38.37 | |
| 3 475 M | |
| 131 M | |
| 615 M | |
| -0.1297 | |
| -0.332 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Wuhan Hiteck Biological Pharma Co Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 615 M
- EBITDA -81 799 856
- Earnings Per Share -1.02
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Wuhan Hiteck Biological Pharma Co Ltd Earnings via APIs
- Latest Release 2024-09-30
- EPS/Forecast NaN
Get Wuhan Hiteck Biological Pharma Co Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
